Posts tagged CF102
Can-Fite CEO to chair cancer conference session

Dr. Pnina Fishman, CEO of Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) will chair the plenary session titled, “Drugs Targeting Adenosine Receptors,” at the 2016 Keystone Symposia J5 in Vancouver, Canada on Jan. 24-28.

This year’s Purinergic Signaling symposium is a joint session with Keystone Symposia J6 Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies. The conference will focus on the leading developments in purinergic receptors, including the A3 adenosine receptor (A3AR) in the treatment of cancer.

Read More
Can-Fite unveils clinical milestones for 2016

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has announced its anticipated clinical milestones for 2016.

“We are very encouraged by the clinical and preclinical data from each of our drugs to date, which indicate their efficacy across six major indications,” CEO, Dr. Pnina Fishman, said in a statement.

Read More